FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Fate Therapeutics
Genocea Biosciences, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Northwestern University
National Cancer Institute (NCI)